Fagereng E, Htwe S, McDonald S, Derocher C, Bertoli M, Carter E
Orphanet J Rare Dis. 2025; 20(1):116.
PMID: 40069831
PMC: 11895252.
DOI: 10.1186/s13023-025-03610-w.
Kalebota N, Laktasic Zerjavic N, Kovac Durmis K, Milosevic M, Andreic A, Koncar B
Turk J Phys Med Rehabil. 2024; 70(3):300-308.
PMID: 39679119
PMC: 11639501.
DOI: 10.5606/tftrd.2024.13140.
Eskes E, van Dussen L, Brands M, Vaz F, Aerts J, van Kuilenburg A
J Inherit Metab Dis. 2024; 48(1):e12789.
PMID: 39177062
PMC: 11670446.
DOI: 10.1002/jimd.12789.
Strand V, Bender S, McCabe D
Rheumatol Ther. 2024; 11(5):1291-1302.
PMID: 39120847
PMC: 11422532.
DOI: 10.1007/s40744-024-00687-w.
Kavanaugh A, Mease P, Gossec L, Ranza R, Tsuji S, Douglas K
ACR Open Rheumatol. 2024; 6(11):736-745.
PMID: 39087872
PMC: 11557994.
DOI: 10.1002/acr2.11714.
Distinction and prognosis of early arthritis phenotypes: an analysis in three European cohorts.
Sepriano A, van Dijk B, Ramiro S, van der Helm-van Mil A, Combe B, van Schaardenburg D
RMD Open. 2023; 9(4).
PMID: 37914180
PMC: 10626756.
DOI: 10.1136/rmdopen-2023-003611.
Long-term fracture risk in rheumatoid arthritis: impact of early sustained DAS28-remission and restored function, progressive erosive disease, body mass index, autoantibody positivity and glucocorticoids. A cohort study over 10 years.
Ajeganova S, Andersson M, Forslind K, Gjertsson I, Nyhall-Wahlin B, Svensson B
BMC Rheumatol. 2023; 7(1):23.
PMID: 37550762
PMC: 10405460.
DOI: 10.1186/s41927-023-00347-6.
Transcutaneous auricular branch vagal nerve stimulation as a non-invasive add-on therapeutic approach for pain in systemic sclerosis.
Bellocchi C, Carandina A, Della Torre A, Turzi M, Arosio B, Marchini M
RMD Open. 2023; 9(3).
PMID: 37536947
PMC: 10401218.
DOI: 10.1136/rmdopen-2023-003265.
Decoding the Clinical Significance of Immunoglobulin G4 in Rheumatoid Arthritis.
Tan L, Sakthiswary R, Veshaaliini U, Shaharir S, Abdul Wahab A, Aziz S
J Clin Med. 2023; 12(14).
PMID: 37510831
PMC: 10380629.
DOI: 10.3390/jcm12144716.
Initial presentation of early rheumatoid arthritis.
Weman L, Salo H, Kuusalo L, Huhtakangas J, Karki J, Vahasalo P
PLoS One. 2023; 18(7):e0287707.
PMID: 37410796
PMC: 10325069.
DOI: 10.1371/journal.pone.0287707.
Efficacy of therapeutic ultrasound in the treatment of chronic calcific shoulder tendinitis: a randomized trial.
cota S, Delimar V, Zagar I, Kovac Durmis K, Kristic Cvitanovic N, Zura N
Eur J Phys Rehabil Med. 2023; 59(1):75-84.
PMID: 36723056
PMC: 10035437.
DOI: 10.23736/S1973-9087.22.07715-2.
Examining Rehabilitation Dose in Adults With Rheumatoid Arthritis: Association With Baseline Factors and Change in Clinical Outcomes.
Thoma L, Wellsandt E, Wipfler K, Michaud K
Arthritis Care Res (Hoboken). 2022; 75(6):1261-1268.
PMID: 36094858
PMC: 10008510.
DOI: 10.1002/acr.25019.
Pain and health-related quality of life in patients with hypophosphatasemia with and without ALPL gene mutations.
Santurtun M, Mediavilla-Martinez E, Vega A, Gallego N, Heath K, Tenorio J
Front Endocrinol (Lausanne). 2022; 13:965476.
PMID: 36072928
PMC: 9442670.
DOI: 10.3389/fendo.2022.965476.
Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
Bergman M, Tundia N, Martin N, Suboticki J, Patel J, Goldschmidt D
Arthritis Res Ther. 2022; 24(1):155.
PMID: 35751108
PMC: 9229430.
DOI: 10.1186/s13075-022-02813-x.
Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App.
Radin M, Arbrile M, Cecchi I, Di Nunzio P, Buccarano N, Di Gregorio F
Int J Environ Res Public Health. 2022; 19(9).
PMID: 35564772
PMC: 9102425.
DOI: 10.3390/ijerph19095379.
Prevalence and Impact of Rheumatologic Pain in Cystic Fibrosis Adult Patients.
Schmoll A, Launois C, Perotin J, Ravoninjatovo B, Griffon M, Carre S
Front Med (Lausanne). 2022; 8:804892.
PMID: 35211488
PMC: 8861186.
DOI: 10.3389/fmed.2021.804892.
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.
McInnes I, Kato K, Magrey M, Merola J, Kishimoto M, Pacheco-Tena C
RMD Open. 2021; 7(3).
PMID: 34663636
PMC: 8524381.
DOI: 10.1136/rmdopen-2021-001838.
[Development of quality standards for patients with rheumatoid arthritis for use in Germany].
Kiltz U, Buschhorn-Milberger V, Albrecht K, Lakomek H, Lorenz H, Rudwaleit M
Z Rheumatol. 2021; 81(9):744-759.
PMID: 34652486
PMC: 9646547.
DOI: 10.1007/s00393-021-01093-1.
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
Takeuchi T, Fleischmann R, Iikuni N, Shi H, Soma K, Paulissen J
Arthritis Res Ther. 2021; 23(1):220.
PMID: 34429160
PMC: 8383419.
DOI: 10.1186/s13075-021-02591-y.
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies.
Genovese M, Durez P, Fleischmann R, Tanaka Y, Furst D, Yamanaka H
Eur J Rheumatol. 2021; 8(3):120-129.
PMID: 34101570
PMC: 9770405.
DOI: 10.5152/eurjrheum.2021.19207.